Navigation Links
Genomic Health Announces Third Quarter 2008 Financial Results and Business Progress
Date:11/5/2008

on expense of $6.9 million in the first nine months of 2008 compared with $4.5 million for the same period in 2007, and $3.6 million of depreciation and amortization expenses, compared with $2.9 million in the same period in 2007.

Recent Highlights and Accomplishments

Commercial Progress

-- More than 10,220 test results delivered in the third quarter of 2008,

compared with more than 5,950 test results delivered in the third

quarter of 2007, an increase of 72 percent year-over-year.

-- More than 75,000 Oncotype DX test results have been delivered to

patients.

-- Gained coverage for an additional 7.9 million lives for reimbursement

of Oncotype DX through contracts, policies and agreements, bringing the

total U.S. covered lives to approximately 89 percent of insured lives

including: Coventry Health Care (4.4 million lives), Blue Cross and

Blue Shield of Massachusetts (1.3 million lives), Medica Health Plans,

HMSA Blue Cross Blue Shield of Hawaii, and WPS Health Insurance in

Wisconsin.

-- Named a Vice President to oversee European markets.

-- Established distribution agreements in Australia and Taiwan.

-- Received test samples from 39 countries to date.

-- Oncotype DX included in the updated 2008 guidelines of the Dutch

Institute for Healthcare Improvement.

Product Pipeline

-- Enhanced clinical utility of Oncotype DX reports by including

quantitative HER2 scores; quantitative estrogen receptor and

progesterone receptor scores were added earlier this year.

-- Completed European study using Oncotype DX in node-negative and

node-positive, breast cancer patients treated with aromatase

inhibitors, which was accepted for oral presentation at the San Antonio

Breast Cancer Symposium in December 2008.

-- Continued to make progress toward a clinical validation
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Transgenomic, Inc. Reports Second Quarter 2007 Results
2. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
3. GeneNews Chief Scientist Dr. C.C. Liew co-editor of new genomics reference book
4. CODA Genomics Announces Issuance of Optimized Synthetic Gene Production Patent
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. WallSt.net (www.wallst.net) Announces Upcoming Interview With CEO of DNAPrint Genomics
7. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
8. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
9. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
10. BioNanoatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
11. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... NASA’s MESSENGER has just celebrated its 10 year anniversary ... one of its latch valves, V27200-818, operating onboard this ... of the planet Mercury. It is only the second ... a vast amount of information and images of the ... solenoids that also include permanent magnets to maintain the ...
(Date:9/16/2014)... jaw movements has been created by a group of ... device can generate electricity from eating, chewing and talking, ... electronic devices, such as hearing aids, cochlear implants, electronic ... of the device,s performance have been published today, 17 ... Structures . , Jaw movements have proved to be ...
(Date:9/16/2014)... BlueInGreen® , a water ... for delivering dissolved gases into liquids, announced the ... a manufacturer’s representative firm to its sales network. ... municipal water and wastewater applications in the Canadian ... founded in 1992 and serves Quebec and Ontario ...
(Date:9/16/2014)... 16, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... completion of the Company,s Investor Day in ... irritable bowel syndrome (IBS) program, including its novel, ... In the keynote presentation, Mark Pimentel ...
Breaking Biology Technology:'Smart material' chin strap harvests energy from chewing 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... MINRAD,International, Inc. (Amex: BUF ) today announced that ... aggregate of $40.0 million of senior,secured convertible notes with ... The notes pay an 8% coupon, have a 3 ... The aggregate net,proceeds of the notes, after deducting the ...
... Biotech and pharma companies,are increasingly utilizing novel ... early in the development cycle to avoid ... and,Biotechnology News (GEN) ( http://www.genengnews.com/ ). By ... early, pharma also has the opportunity to ...
... Scientific,Corporation (NYSE: BSX ) announced today that ... issued its ruling in an,arbitration between the Company ... pursuant to the 2005 settlement agreement between,the companies, ... various U.S. and European patents held by Medinol. ...
Cached Biology Technology:MINRAD International, Inc. Announces $40.0 Million Private Placement 2MINRAD International, Inc. Announces $40.0 Million Private Placement 3Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 2WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents 3
(Date:9/16/2014)... interaction between viruses, bacteria, and their environment is ... collaboration between Matthew Sullivan, associate professor in the ... Biology and Steven Hallam from the University of ... are drivers of nutrient and energy cycles that ... is changing, so are the environments these bacteria ...
(Date:9/16/2014)... Schizophrenia is associated with increased rates and intensity of ... that the relationship between schizophrenia and smoking stems, in ... to self-medicate symptoms and cognitive impairment associated with the ... issue of Biological Psychiatry , sheds light on ... nicotine receptors in the brain was lower in schizophrenia ...
(Date:9/16/2014)... Proteins are responsible for practically all vital functions ... reactions, forward signals, transport particular substances and control ... that proteins do not function independently of each ... you examine the protein networks, you find many ... Falter-Braun from TUM,s Chair of Plant Systems Biology. ...
Breaking Biology News(10 mins):New research decodes virus-host interactions in ocean dead zones 2New research decodes virus-host interactions in ocean dead zones 3Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2
... The Society of Interventional Radiology Foundation,s Discovery Campaign, ... invasive medicine into new areas of discovery, announced ... a manufacturer of medical devices, pharmaceuticals and medical ... and is a "Visionary" level supporter. ...
... In the waters off the North Carolina coast, historically-significant ... seafloor, a testament to a relatively unknown chapter in ... shipwrecks are not only important for their cultural value, ... fishes, invertebrates and algal species. Additionally, due to their ...
... by two teams of Army scientists and collaborators has identified ... virus infection. The findings, published online today in separate studies ... for combating one of the world,s most deadly viruses. ... high as 90 percent in humans. The virus is of ...
Cached Biology News:Single protein, key to ebola virus infection, could aid in drug design 2
ImageQuant 300, 1 EA. Category: ImageQuant CCD Imagers....
Recombinant Feline IL-12/IL-23 p40 (C-Terminus), CF...
Request Info...
Recombinant Feline IL-5...
Biology Products: